Revance Therapeutics (NASDAQ:RVNC – Get Rating) posted its earnings results on Tuesday. The biopharmaceutical company reported ($0.74) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.01, Briefing.com reports. Revance Therapeutics had a negative return on equity of 786.70% and a negative net margin of 268.87%. The firm had revenue of […]
Revance Therapeutics (NASDAQ:RVNC – Get Rating) issued its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($0.74) EPS for the quarter, topping the consensus estimate of ($0.75) by $0.01, Briefing.com reports. Revance Therapeutics had a negative net margin of 268.87% and a negative return on equity of 786.70%. The firm had revenue of $49.33 […]
Shares of Revance Therapeutics, Inc. (NASDAQ:RVNC – Get Rating) reached a new 52-week high on Monday . The stock traded as high as $36.65 and last traded at $36.60, with a volume of 1859741 shares traded. The stock had previously closed at $34.61. Wall Street Analysts Forecast Growth A number of research analysts recently commented […]
Revance Therapeutics, Inc. (NASDAQ:RVNC – Get Rating) CFO Tobin Schilke sold 3,201 shares of the firm’s stock in a transaction dated Monday, May 1st. The stock was sold at an average price of $31.70, for a total value of $101,471.70. Following the transaction, the chief financial officer now owns 63,081 shares in the company, valued […]